MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

Liu, Yuan Yuan; Zhao, Ren; Liu, Chao; Zhou, Jie; Liu, Yang; Li, Li

doi:10.3389/fonc.2022.881496

Cited by 7 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these 12 m 7 G-miRNAs, four belong to the miR-320 family, known for anti-oncogene target miRNA for cancer therapy ( Liang et al, 2021 ). Notably, miR-320b and miR-320d were identified as prediction biomarkers for platinum resistance in ovarian cancer patients ( Liu et al, 2022 ). Aberrant expression of miR-320e, let-7a-5p and miR-92b-3p have been acknowledged as a prognostic biomarker in colorectal cancer ( Perez-Carbonell et al, 2015 ; Pichler et al, 2017 ; Bustos et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

A novel serum m7G-harboring microRNA signature for cancer detection

Chen,

Xie,

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

Background: Emerging evidence points to the exceptional importance and value of m7G alteration in the diagnosis and prognosis of cancers. Nonetheless, a biomarker for precise screening of various cancer types has not yet been developed based on serum m7G-harboring miRNAs.Methods: A total of 20,702 serum samples, covering 12 cancer types and consisting of 7,768 cancer samples and 12,934 cancer-free samples were used in this study. A m7G target miRNA diagnostic signature (m7G-miRDS) was established through the least absolute shrinkage and selection operator (LASSO) analyses in a training dataset (n = 10,351), and validated in a validation dataset (n = 10,351).Results: The m7G-miRDS model, a 12 m7G-target-miRNAs signature, demonstrated high accuracy and was qualified for cancer detection. In the training and validation cohort, the area under the curve (AUC) reached 0.974 (95% CI 0.971–0.977) and 0.972 (95% CI 0.969–0.975), respectively. The m7G-miRDS showed superior sensitivity in each cancer type and had a satisfactory AUC in identifying bladder cancer, lung cancer and esophageal cancer. Additionally, the diagnostic performance of m7G-miRDS was not interfered by the gender, age and benign disease.Conclusion: Our results greatly extended the value of serum circulating miRNAs and m7G in cancer detection, and provided a new direction and strategy for the development of novel biomarkers with high accuracy, low cost and less invasiveness for mass cancer screening, such as ncRNA modification.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel serum m7G-harboring microRNA signature for cancer detection

Chen,

Xie,

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…These members also exhibited the capability to activate ADSCs, though less effectively than miR-320a. Prior research has indicated potential associations between miR-320b and miR-320d and platinum resistance in OC patients [ 47 ]. Furthermore, plasma exosomal miR-320d has shown promise as a noninvasive and effective diagnostic biomarker for OC [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells

Gong,

Li,

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Background Omental metastasis is the major cause of ovarian cancer recurrence and shortens patient survival, which can be largely attributed to the dynamic evolution of the fertile metastatic microenvironment driven by cancer cells. Previously, we found that adipose-derived mesenchymal stem cells (ADSCs) undergoing a phenotype shift toward cancer-associated fibroblasts (CAFs) participated in the orchestrated omental premetastatic niche for ovarian cancer. Here, we aim to elucidate the underlying mechanisms. Methods Small extracellular vesicles were isolated from ovarian cancer cell lines (ES-2 and its highly metastatic subline, ES-2-HM) and patient ascites using ultracentrifugation. Functional experiments, including Transwell and EdU assays, and molecular detection, including Western blot, immunofluorescence, and RT–qPCR, were performed to investigate the activation of ADSCs in vitro. High-throughput transcriptional sequencing and functional assays were employed to identify the crucial functional molecules inducing CAF-like activation of ADSCs and the downstream effector of miR-320a. The impact of extracellular vesicles and miR-320a-activated ADSCs on tumor growth and metastasis was assessed in subcutaneous and orthotopic ovarian cancer xenograft mouse models. The expression of miR-320a in human samples was evaluated using in situ hybridization staining. Results Primary human ADSCs cocultured with small extracellular vesicles, especially those derived from ES-2-HM, exhibited boosted migration, invasion, and proliferation capacities and elevated α-SMA and FAP levels. Tumor-derived small extracellular vesicles increased α-SMA-positive stromal cells, fostered omental metastasis, and shortened the survival of mice harboring orthotopic ovarian cancer xenografts. miR-320a was abundant in highly metastatic cell-derived extracellular vesicles, evoked dramatic CAF-like transition of ADSCs, targeted the 3′-untranslated region of integrin subunit alpha 7 and attenuated its expression. miR-320a overexpression in ovarian cancer was associated with omental metastasis and shorter survival. miR-320a-activated ADSCs facilitated tumor cell growth and omental metastasis. Depletion of integrin alpha 7 triggered CAF-like activation of ADSCs in vitro. Conclusions miR-320a in small extracellular vesicles secreted by tumor cells targets integrin subunit alpha 7 in ADSCs and drives CAF-like activation, which in turn facilitates omental metastasis of ovarian cancer. Graphical Abstract

show abstract

“…All the research reports mentioned above on the effects of hsa-miR-320d on the relative cancers showed that the relative effects of hsa-miR-320d were altogether negatively oncogenic, as hsa-miR-320d was a potential tumor suppressor. [114,117–127] The expression of hsa-miR-320d was significantly decreased in the cancer tissue and/or the peripheral serum of patients, [114,117–119,123,124,126] which was a loss of negative effect of hsa-miR-320d as a potential tumor suppressor. A lower expression level of hsa-miR-320d, either in cancer tissue or in peripheral serum, was positively correlated with the related tumorigenesis and development, adverse tumor phenotypes or prognosis, like bigger tumor size, advanced clinic stages, lymph node metastasis, chemoresistance, recurrence, or shorter overall and disease-free survival, etc.…”

Section: Discussionmentioning

confidence: 99%

“…As to hsa-miR-320d in cancers, there have been several special research reports, like on colorectal cancer, [117][118][119][120][121] on lung cancer, [122] on HCC, [114] on ovarian cancer, [123,124] on prostate cancer [10,125] and on chordoma. [126,127] But, until now, there is not any special research report on the potential values of exosomal hsa-miR-320d in the EC clinic and the relative research.…”

Section: The Potential Values Of Exosomal Hsa-mir-320d In Ecmentioning

confidence: 99%

See 1 more Smart Citation

Four differentially expressed exosomal miRNAs as prognostic biomarkers and therapy targets in endometrial cancer: Bioinformatic analysis

Yao,

Shi,

Zhu

2023

Medicine

View full text Add to dashboard Cite

Endometrial cancer (EC) is one of the most common gynecological malignancies worldwide. Accumulated evidence has demonstrated exosomes of cancer cells carry microRNAs (miRNAs) to nonmalignant cells to induce metastasis. Our study aimed to find possible biomarkers of EC. Data for miRNA expression related with exosome from EC patients were downloaded from The Cancer Genome Atlas database, and the miRNA expression profiles associated with exosomes of EC were downloaded from the National Center for Biotechnology Information. We used different algorithms to analyze the differential miRNA expression, infer the relative proportion of immune infiltrating cells, predict chemotherapy sensitivity, and comprehensively score each gene set to evaluate the potential biological function changes of different samples. The gene ontology analysis and Kyoto encyclopedia of genome genomics pathway analysis were performed for specific genes. A total of 13 differential miRNAs were identified, of which 4 were up-regulated. The 4 miRNAs, that is hsa-miR-17-3p, hsa-miR-99b-3p, hsa-miR-193a-5p, and hsa-miR-320d, were the hub exosomal miRNAs that were all closely related to the clinic phenotypes and prognosis of patients. This study preliminarily indicates that the 4 hub exosomal miRNAs (hsa-miR-17-3p, hsa-miR-99b-3p, hsa-miR-193a-5p, and hsa-miR-320d) could be used as prognostic biomarkers or therapy targets in EC. Further studies are required to make sure of their real feasibility and values in the EC clinic and the relative research.

show abstract

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

Cited by 7 publications

References 44 publications

A novel serum m7G-harboring microRNA signature for cancer detection

A novel serum m7G-harboring microRNA signature for cancer detection

Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells

Four differentially expressed exosomal miRNAs as prognostic biomarkers and therapy targets in endometrial cancer: Bioinformatic analysis

Contact Info

Product

Resources

About